CDT Equity (NASDAQ:CDT) Stock Rating Lowered by Wall Street Zen

CDT Equity (NASDAQ:CDT) was downgraded by Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

CDT Equity Stock Down 10.8%

Shares of NASDAQ CDT opened at $0.64 on Friday. The firm has a market cap of $3.09 million, a PE ratio of -0.00 and a beta of 1.44. CDT Equity has a 12-month low of $0.57 and a 12-month high of $610.00. The company’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $16.66.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.